Mesothelin (MSLN) is a tumor-associated glycoprotein overexpressed in NSCLC and mesothelioma, associated with poor prognosis and resistance to chemotherapy, and has limited expression in normal tissues, making it an attractive CAR T-cell target. This evidence concerns the gene MSLN and non-small cell lung carcinoma.